Ask AI
LEAP-002: Primary Results
LEAP-002: Placebo-Controlled Phase III Trial of Lenvatinib ± Pembrolizumab as First-line Therapy for Advanced HCC

Released: September 19, 2022

Activity

Progress
1
Course Completed